News Related to European Society of Gynaecological Oncology

Related coverage linked through entity extraction aliases.

Experimental drug elenagen doubles survival in mid-stage ovarian cancer trial

Apr 11, 2026

An experimental ovarian cancer drug, elenagen, more than doubled median survival in a 30-patient mid-stage trial in Belarus. The drug was added to gemcitabine and reduced mortality risk by nearly 60%.

KEYTRUDA Plus Chemotherapy Improves Survival in Platinum-Resistant Ovarian Cancer

Mar 02, 2026

Final analysis of Merck's Phase 3 KEYNOTE-B96 trial shows KEYTRUDA plus paclitaxel with or without bevacizumab significantly improved overall survival in platinum-resistant recurrent ovarian cancer patients, reducing death risk by 18%.